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Abstract
Introduction: Recent developments in treatment have steadily raised the median predicted age of survival for people with Cystic 
Fibrosis (CF). We report the health-related quality of life (HRQoL) in CF adult patients and correlate our findings with the patients’ 
demographic characteristics.
Material and methods: The Cystic Fibrosis Quality of Life (CFQoL) questionnaire was answered by 77 CF adult patients. The 
questionnaire included questions pertaining to age, sex and level of education and covered eight sections of functioning.
Results: The highest score was reported in the “Social Functioning” section, while the lowest in the “Concerns for the Future” sec-
tion. When different age groups were compared, statistical significances were reported in “Physical Functioning”, “Interpersonal 
Relationships”, and the “Career Concerns” section, with older patients reporting statistically higher HRQoL scores than younger 
ones (p < 0.005). No statistically significant difference was reported amongst the scoring between male and female CF patients. 
When different educational levels were compared, patients that had received a higher educational training scored statistically 
higher in all but one sections of the questionnaire when compared with patients of a lower educational level (p < 0.005).
Conclusion: More than half Greek adult CF patients report that they are capable to participate in social activities but most of them 
are worried about the outcome of their disease and its effect on their lives. 
Key words: cystic fibrosis, quality of life, adults, Greece
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Introduction
CF, the commonest severe autosomal recessi-
ve disorder in Caucasians with an average rate of 
1/1,800−8,000 living births, affects approxima-
tely 80,000 patients worldwide [1−3]. Although 
recent developments in treatment have steadily 
raised the median predicted age of survival for 
people with CF over the last 25 years (in 2011, 
the age was 36.8 years) [4], the topic of health-re-
lated quality of life (HRQoL) measurement in CF 
remains still under intense scrutiny and research.
Standard guidelines of CF care include a 
multidisciplinary approach to the patient with 
CF (nutrition, lung health, infection control, age
-specific care) [3]. However, an integral part of the 
patient’s well being is the HRQoL, which must 
evaluate any physical symptom, the patient’s 
functional status, their psychological and emotio-
nal state as well as any level of social functioning 
[5]. The patient’s perspective (as depicted through 
the HRQoL) can be an extremely helpful as it can 
guide both research and clinical practice [6].
In this institutional study, we report, for 
the first time in Greece, the HRQoL in CF adult 
patients with the use of a questionnaire and cor-
relate our findings with the patients’ age, gender 
and educational level.
Material and methods
Questionnaire
The Cystic Fibrosis Quality of Life (CFQoL) 
questionnaire was used, as previously described 
[7]. We chose this appropriately validated for use 
in CF studies questionnaire since it has not only 
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Table 1. The sections covered by the questionnaire
Section Number  
of questions 
(52)
Score from 1 to 6 Cronbach’s 
Alpha
Physical functioning 10 All the time/most of the time/good bit of the time/sometimes/occasionally/never 0.959
Social functioning 4 All the time/most of the time/good bit of the time/sometimes/occasionally/never 0.892
Treatment 
Treatment issues 
Chest symptoms 
7
4
3
All the time/most of the time/good bit of the time/sometimes/occasionally/never
0.819
0.910
Emotional functioning 8 All the time/most of the time/good bit of the time/sometimes/occasionally/never 0.941
Concerns for the future 6 Strongly agree/agree/slightly agree/slightly disagree/disagree/strongly disagree 0.845
Interpersonal  
relationships
10 Strongly agree/agree/slightly agree/slightly disagree/disagree/strongly disagree 0.941
Body image 3 Strongly agree/agree/slightly agree/slightly disagree/disagree/strongly disagree 0.832
Career concerns 4 Strongly agree/agree/slightly agree/slightly disagree/disagree/strongly disagree 0.959
been previously used on an adult CF population 
but has, also, undergone appropriate psychome-
tric testing in CF [6].
The questionnaire included questions perta-
ining to age, sex and level of education (n = 3) and 
covered eight sections of functioning (n = 52). 
The scoring scales were designed to reflect po-
sitive and negative scoring (Table 1).
Participants and data collection
After explanation of the purposes of the study, 
77 CF patients agreed to respond to the CFQoL 
questionnaire. The diagnosis of CF consisted of 
finding specific clinical (phenotypic) character-
istics in combination with biochemical or genet-
ic markers of CF transmembrane conductance 
regulator (CFTR) dysfunction, as proposed by 
the European Union Cystic Fibrosis Diagnostic 
Working Group [8]. The patients were assured that 
participation was voluntary and that they were 
free to withdraw any time they wanted. Their 
anonymity in completing the questionnaire was 
also assured along with the remark that any data 
collected would not be used for other purposes. 
No participant withdrew from the survey. Data 
collection was performed from January 1st 2013 
to June 1 st 2013 by the same investigator. All 
data were saved in a database. The survey was 
performed in the adult Cystic Fibrosis Unit of the 
“Sismanogleio” General Hospital of Attica, Greece.
No patient had undergone lung transplanta-
tion in the past.
Statistical analysis
The score of all the questions was added. All 
items were scored 1 to 6 (except question 6 of the 
“Physical Function” Section which had a rever-
se scoring). Raw scores of 3 or under indicated 
a negative response. Transformed scores that 
translated to values between 0 and 100 indicated 
the value that had been achieved out of a maxi-
mum of 100 with 100 indicating the most positive 
HRQoL levels possible. The Cronbach’s Alpha 
factor was calculated so as to check the reliability 
of the aforementioned scores. In order to compa-
re the HRQoL with the basic demographic data, 
a one way fluctuation analysis was used (ANOVA 
F-test), the middle value was compared with 2 
independent samples (t-test) and the Spearman 
r correlation coefficient was calculated.
A p-value < 0.05 was considered statistically 
significant. Data were analyzed using the statisti-
cal software for social sciences (SPSS, Chicago, 
USA, version 17).
Results
Response ratio was 100%. No patient refused 
to participate in the study. The demographic cha-
racteristics of the study population are shown in 
Table 2. The Cronbach’s Alpha factor for the sum 
of the scores was above 80% (minimum 81.9% 
and maximum 95.9%), revealing remarkable re-
liability in our results (Table 1).
The highest score (62.5/100) was reported 
in the “Social Functioning” section, while the 
lowest (26.6/100) in the “Concerns for the Future” 
section (Fig. 1). Patients reported a lower HRQoL 
in the sections of “Body Image”, “Interpersonal 
Relations” and “Carrer Concerns”.
When the HRQoL was compared to the pa-
tients’ gender, there was no statistically signi-
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Table 2.  Demographic characteristics of the study  
population
Patients (n = 77) (%)
Gender
Male
Female
34
43
44.2
55.8
Age (years)
18−23
24−28
29−33
> 33
22
18
18
19
28.7
23.3
22.3
24.7
Educational level
None
Primary1 
Secondary2
Tertiary3
4
6
26
41
5.2
7.8
33.8
53.2
1Primary education pertains to primary school spanning six years (ages 6 to 12)
2Secondary education comprises two stages: a compulsory three-year school 
(middle or junior high school), followed by a non compulsory three-year aca-
demically oriented high school (unified upper secondary schools or technical- 
-vocational educational institutes (ages 12−18)
3Tertiary education is provided by Universities, Polytechnics, Technological 
Educational Institutes and Academies (ages 18 and above)
Figure 1. The graph depicting the middle value and the 95% CI for the section scores in patients with cystic fibrosis
ficant difference amongst the scoring reported 
between male and female CF patients (p > 0.05). 
However, the questionnaire revealed some score 
differences indicative of some tendencies. In the 
“Treatment Issues” subsection, the middle score 
difference between female and male patients was 
7.1 indicating that male patients have poorer 
HRQoL (p = 0.291). Likewise, in the “Concerns for 
the Future” section, the male patients outscored 
the female patients by a middle value of 7.4 (p = 
0.211). Additionally, in the “Body Image” section, 
male patients reported lower scores than female 
patients (middle score difference of 12.2) (p = 
0.118) (Table 3).
When different age groups were compared, 
in the “Physical Functioning” section, older pa-
tients reported statistically higher HRQoL scores 
than younger ones (p = 0.006), with the middle 
scoring difference between patients 33 years or 
older and younger patients ranging from 13.7 to 
28.5. In the “Interpersonal Relationships” section, 
patients younger than 33 years reported statisti-
cally significant poorer HRQoL by scoring less in 
the questionnaire (p = 0.039), with the middle 
scoring difference between patients 33 years or 
older and younger patients ranging from 10.2 to 
25. Besides, the analysis revealed a statistical 
deference in the “Career Concerns” section, since 
older patients scored higher than younger ones. 
The middle score difference in the 33 years or 
older group when compared to the others ranged 
from 5.7 to 30.8 (p = 0.013) (Table 3).
Finally, when analyzing the patients’ educa-
tional level, in the “Physical Functioning” section, 
patients who had received tertiary educational 
training reported statistically higher scores when 
compared to other patients. The middle score dif-
ference was 41.5 in comparison to patients who 
had received none/primary educational training 
and 18 to those with secondary educational tra-
ining (p<0.001). Similar results were reported in 
the “Social Functioning” section where the middle 
score difference was 31.2 and 15.2, respectively 
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(p = 0.001). Patients who had received none/pri-
mary and secondary educational training scored 
significantly lower when compared to tertiary 
education patients in the “Treatment” section. 
More specifically, the middle score difference was 
33.9 and 9.2, respectively, in the “Treatment Issu-
es” subsection (p = 0.002) and 48.3 and 19.6, re-
spectively, in the “Chest Symptoms” subsection (p 
= 0.001). Furthermore, patients with lower educa-
tional training reported significantly lower scores 
as opposed to tertiary educational level patients 
in the “Emotional Functioning” section (middle 
score difference was 34.9 for the none/primary 
educational level patients and 17.4 for the secon-
dary educational level patients when compared to 
the tertiary educational level group, p = 0.001). 
Regarding the “Interpersonal Relationships” sec-
tion, patients with a tertiary education training 
reported a 26.3 score difference when compared 
to patients with no/primary education and 13.4 
score difference when compared to patients with 
secondary education (p = 0.011). In the “Body 
Image” section, results were similar with patients 
having received a tertiary education training re-
porting a statistically higher HRQoL (middle score 
difference of 25 with no/primary educational 
level patients and 18 with secondary educational 
level patients) (p = 0.025). In the “Career Con-
cerns” section the scoring revealed that patients 
of a lower educational level reported a statistically 
lower HRQoL, with the middle score difference 
between patients of tertiary educational level and 
patients of no/primary educational level being 31 
and that between patients of tertiary educational 
level and patients of secondary educational level 
being 26.2 (p = 0.001). Interestingly enough, 
although not statistically significant, the results 
revealed higher scores reported by patients ha-
ving received a tertiary education than patients 
of a lower educational level in the “Concerns for 
the Future” section (middle score difference of 
15.2 and 10.7, respectively) (p = 0.084). 
Discussion
The definition of HRQoL comprises of several 
multifactorial domains as reported by the patient 
him/herself. It is of the outmost importance in 
clinical practice as the correlations between cli-
nical variables and HRQoL are often poor. It is 
the HRQoL that can provide valuable information 
not reported by other outcomes. The patients’ 
perspective regarding their well being or how they 
cope with the treatment can provide a reliable 
and cheap way of standardizing and evaluating 
therapeutic schemes and interventions [9]. The-
refore, HRQoL scales can be used (except from 
presenting the illness impact on the patients’ 
daily functioning and coping) to guide clinical 
decision, to estimate the cost effectiveness of 
a specific drug, to evaluate surgical interventions, 
and, last but not least, to report outcomes in cli-
nical trials [10, 11].
Since, as described above, the HRQoL is, 
by definition, a multidimensional concept, it is 
logical that different types of scales have been 
used in CF studies with, sometimes, inconsistent 
findings. Scientists and researchers agree that 
there is no “gold standard” on measuring HRQoL 
in CF patients through the use of questionnaires. 
Furthermore, the disease itself has had many 
breakthroughs (regarding available therapeutic 
modalities) since the first attempts to measure 
HRQoL were undertaken, rendering the signi-
ficance of previous reported data sometimes 
questionable [6]. Our study is the first study 
in Greece that reports the HRQoL in CF adult 
patients and associates these results with their 
demographic characteristics.
Regarding the HRQoL, the highest score 
was reported in the “Social Functioning” section 
and the lowest in the “Concerns for the Future” 
section, rendering more than half of these pa-
tients capable to participate in social activities. 
However, most of them are worried about the 
outcome of their disease and its effect on their 
lives. Besides, the consistent low scores reported 
on the sections of “Body Image”, “Interpersonal 
Relations” and “Career Concerns” clearly indicate 
that Greek adult CF patients are characterized by 
low self esteem that reflects on how they react and 
cope with others and are very skeptics regarding 
any chance for professional evolvement.
Studies have reported that CF patients of 
increased age score less in respect of physical 
and social functioning, career concerns and in-
terpersonal relationships when measuring their 
HRQoL. On the other hand, they seem to report 
a better HRQoL when measuring their concerns 
for the future, perhaps due to their constant 
re-evaluation through time of what really matters 
in life [12, 13]. Our study revealed that when dif-
ferent age groups were compared, older patients 
(33 years and older) scored less both in the “Phys-
ical Functioning” as well as in the “Interpersonal 
Relationships” section, as expected. However, 
they also reported a better HRQoL regarding 
their “Career Concerns”, in contrast with other 
findings. Perhaps the better clinical outcomes 
reported by the advantages in CF therapy makes 
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our study group cope better regarding its career 
expectations. No other statistical significance was 
noted in our study.
Clinical studies in CF populations have, 
also, confirmed that there are gender differences 
in the reported HRQoL with women of any age 
(children, adolescents, and adults) scoring less in 
HRQoL scales than men [14−16]. Female patients 
have reported a poorer HRQoL when it comes to 
physical, emotional and psychological function-
ing as well as chest symptoms (even girls have 
reported poorer chest symptoms than boys with 
no difference in their FEV1) [6, 17]. Interestingly 
enough, women seem to have a more accurate 
perception of their objective clinical status than 
men [16]. This might explain the fact that in some 
studies women have scored more in the HRQoL 
questionnaire regarding interpersonal relation-
ships and body image [12, 13, 18, 19]. However, 
the aforementioned results could not be validated 
in our study since we showed no statistical signifi-
cance between adult gender groups. Nevertheless, 
our data revealed a trend of women scoring less 
in the “Treatment Issues”, the “Concerns for the 
Future” and the “Body Image” section. Perhaps 
the small number of patients (when compared 
to other published studies) or the fact that no 
clinical (i.e. FEV1) or psychosocial variables (i.e. 
depression, anxiety) were taken into account 
could explain these discrepancies in results.
When trying to compare our results with 
other studies, data are interesting. A recent 
study investigating factors related to changes in 
the quality of life among Polish adolescents and 
adults with CF over a 1-year period, revealed that 
better baseline spirometry (and, therefore, sys-
tematic chronic therapy) was a predictive factor 
for improvement in treatment issues and career 
concerns. Maintaining good physical condition 
and activity seemed to correlate positively with 
future and career concerns, while residents in 
rural areas or living under difficult conditions 
were especially vulnerable to deterioration in 
future concerns [20].
The American Project on Adult Care in CF, 
a prospective, longitudinal panel study of 333 
adult CF patients, assessed both physical and 
psychosocial domains of health via the CF Ques-
tionnaire-Revised (CFQ-R), seven times over 
21 months. The results revealed that lung function, 
frequency of pulmonary exacerbations, and nu-
tritional indices were associated with physical 
CFQ-R domain scores, as expected. However, 
population changes in several psychosocial do-
mains of the CFQ-R suggested that differentiating 
between the physical and the psychosocial trajec-
tories in health among adults with CF is critical 
in evaluating patient-reported outcomes [21]. 
To make things even more difficult for the 
physician to interpret, only recently, Abbott et 
al. undertook a longitudinal observational study 
enrooling 234 participants aged 14−48 years from 
large adult CF centres in the United Kingdom. 
Observations were obtained at seven time points: 
approximately every 2 years over a 12-year peri-
od. The authors revealed that demographic and 
changes in clinical variables were independently 
associated with a change in HRQoL over time. 
They came to the conclusion that cross-sec-
tional data are inadequate when evaluating the 
relationships between HRQoL domains and key 
demographic and clinical variables, as they fail 
to recognise the full impact of the CF disease tra-
jectory and its treatments on quality of life [22].
Our study is the first one to report the in-
fluence of the patients’ educational level on 
their HRQoL. Patients that had received a higher 
(tertiary) educational training scored statistically 
higher on almost all sections of the question-
naire when compared with patients of a lower 
educational level. Even in the “Concerns for 
the Future” section, the data analysis revealed 
a tendency for higher scores amongst better ed-
ucated patients. Given the fact that the patients’ 
educational training should lead to a more ful-
filling job and that the increased life expectancy 
in CF patients has helped more people with CF 
entering the workforce [23], it is possible for the 
work environment to provide a form of social 
scaffolding and make better educational trained 
CF individuals cope better with their disease. 
A recent HRQoL evaluation in a Polish adolescent 
population with CF (aged 14−18 years) revealed 
that school attendance had a significant impact 
on many aspects of the adolescents’ functioning 
[24], validating, in part, our findings.
Limitations
As mentioned before, the number of patients 
was relative small when compared to other 
studies. Besides, no clinical or psychosocial 
variables were taken into consideration when 
analyzing the patients’ reported HRQoL. As, 
already reported, the predicted FEV1 % and pul-
monary exacerbations have the broadest impact 
on HRQoL in CF patients [19]. 
Last, but not least, our study did not assess 
the financial status of each patient and its effect 
on their quality of life. The BURQOL-RD Research 
Network investigating the social economic bur-
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den and health-related quality of life in patients 
with rare diseases in Europe, has shown that the 
annual cost for a CF patient is high, with indirect 
costs relating to informal care and early retire-
ment baring significant societal implications. 
Studies so far, have revealed that in economic 
vulnerable populations the risk factors for wor-
se health outcomes are increased [25, 26]. This 
could be of paramount importance for a country 
like Greece, facing over the last years a dramatic 
economic crisis with tremendous implications in 
the well-being of each patient.
Conclusions
Repeated HRQoL measurement through clini-
cal studies should be undertaken so as to improve 
the care delivered to patients and provide useful in-
formation concerning the individual’s adaptation to 
the disease. Patients’ outcomes should be reported 
in well planned clinical trials as an additional out-
come parameter. Our results showed that a higher 
educational training seems to improve the quality 
of life of adult CF patient; perhaps a better and more 
rewarding working environment can enhance the 
patients’ ability to cope with their disease.
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